©The Author(s) 2026.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 112742
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.112742
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.112742
Table 10 Train-of-Four monitoring and neuromuscular blockade effect evaluation
| Indicator | Sarcopenia group (n = 35) | Non-sarcopenia group (n = 65) | t-test | P value |
| Time to TOF count = 0 for intubation (min) | 2.3 ± 0.4 | 3.0 ± 0.6 | -6.284 | < 0.001 |
| First supplemental dose time (min) | 42.8 ± 10.2 | 58.4 ± 12.8 | -6.124 | < 0.001 |
| TOF ratio recovery to 0.7 time (min) | 55.2 ± 11.8 | 75.6 ± 16.2 | -6.486 | < 0.001 |
| TOF ratio recovery to 0.9 time (min) | 65.8 ± 13.6 | 89.2 ± 18.8 | -6.824 | < 0.001 |
| Intubation condition score (excellent rate %) | 100 | 100 | - | - |
- Citation: Li ZW, Liu Z, Liu SQ. Muscle mass correlates with rocuronium distribution volume and guides dose optimization in obese colorectal cancer patients. World J Gastrointest Oncol 2026; 18(1): 112742
- URL: https://www.wjgnet.com/1948-5204/full/v18/i1/112742.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.112742